{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:18Z","timestamp":1740107718899,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000948","name":"Pfizer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To describe treatment patterns and persistence of tofacitinib, interleukin 17 inhibitors (IL-17Ai) and tumour necrosis factor inhibitors (TNFi), in patients with psoriatic arthritis (PsA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from adult patients with PsA and who had received at least one prescription of tofacitinib, IL-17Ai or TNFi between May 2019 and September 2021 were sourced from the Australian OPAL dataset. Persistence, analysed via Kaplan\u2013Meier methods, and propensity score matching between tofacitinib and bDMARD (IL-17Ai and TNFi) groups were conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 16,692 patients with PsA, 1486 (<jats:italic>n<\/jats:italic>\u2009=\u2009406 tofacitinib, <jats:italic>n<\/jats:italic>\u2009=\u2009416 IL-17Ai and <jats:italic>n<\/jats:italic>\u2009=\u2009664 TNFi) were included. More females were in the tofacitinib group (75.4%) than in the IL-17Ai (61.1%) and TNFi (64.8%) groups. Overall, 19.2% of tofacitinib patients were first line, compared with 41.8% of IL-17Ai and 62.8% of TNFi patients. In the overall population, the median persistence was 16.5 months (95% CI 13.8 to 19.5 months), 17.7 months (95% CI 15.8 to 19.6 months) and 17.2 months (95% CI 14.9 to 20.5 months) in the tofacitinib, IL-17Ai and TNFi groups, respectively. Persistence was similar in the tofacitinib\/IL-17Ai matched population; however, in the tofacitinib\/TNFi matched population, persistence was longer in the tofacitinib group (18.7 months, 95% CI 15.6 to 21.4 months) compared with the TNFi group (12.2 months, 95% CI 19.9 to 14.9 months).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this Australian real-world dataset, tofacitinib was more frequently used in later lines and among a slightly higher proportion of female patients than IL-17Ai or TNFi. Overall, treatment persistence was similar for tofacitinib, IL-17Ai and TNFi, but tofacitinib exhibited longer persistence than TNFi in a matched population.<\/jats:p>\n                <jats:p><jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>This is the first, large real-world study from Australia investigating the demographics, treatment patterns and comparative treatment persistence of patients with psoriatic arthritis (PsA) treated with tofacitinib and biologic disease-modifying drugs (bDMARDs).<\/jats:italic>\u2022 <jats:italic>The study suggests that tofacitinib is an effective intervention in PsA with at least comparable persistence to bDMARDs: tumour necrosis factor inhibitors (TNFi) and interleukin-17 A inhibitors (IL-17Ai).<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-024-06930-7","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T02:01:38Z","timestamp":1709949698000},"page":"1579-1589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-055X","authenticated-orcid":false,"given":"Geoffrey","family":"Littlejohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Leadbetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-4065","authenticated-orcid":false,"given":"Belinda E.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Feletar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0564-9768","authenticated-orcid":false,"given":"Catherine","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-9712","authenticated-orcid":false,"given":"Tegan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7213-9461","authenticated-orcid":false,"given":"David","family":"Witcombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-4981","authenticated-orcid":false,"given":"Ho Yin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-3999","authenticated-orcid":false,"given":"Peter","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"issue":"Suppl 2","key":"6930_CR1","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 64(Suppl 2):ii14-7. https:\/\/doi.org\/10.1136\/ard.2004.032482","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"6930_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00296-017-3760-z","volume":"37","author":"ME Husni","year":"2017","unstructured":"Husni ME, Betts KA, Griffith J, Song Y, Ganguli A (2017) Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective. Rheumatol Int 37(9):1423\u20131434. https:\/\/doi.org\/10.1007\/s00296-017-3760-z","journal-title":"Rheumatol Int"},{"key":"6930_CR3","doi-asserted-by":"publisher","first-page":"711823","DOI":"10.3389\/fmed.2021.711823","volume":"8","author":"JW Bolt","year":"2021","unstructured":"Bolt JW, van Ansenwoude CMJ, Hammoura I, van de Sande MG, van Baarsen LGM (2021) Translational research studies unraveling the origins of psoriatic arthritis: moving beyond skin and joints. Front Med (Lausanne) 8:711823. https:\/\/doi.org\/10.3389\/fmed.2021.711823","journal-title":"Front Med (Lausanne)"},{"key":"6930_CR4","doi-asserted-by":"publisher","unstructured":"Ocampo DV, Gladman D (2019) Psoriatic arthritis. F1000Res 8. https:\/\/doi.org\/10.12688\/f1000research.19144.1","DOI":"10.12688\/f1000research.19144.1"},{"issue":"1","key":"6930_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12016-016-8529-8","volume":"51","author":"A Sukhov","year":"2016","unstructured":"Sukhov A, Adamopoulos IE, Maverakis E (2016) Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review. Clin Rev Allergy Immunol 51(1):87\u201399. https:\/\/doi.org\/10.1007\/s12016-016-8529-8","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"6930_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","volume":"14","author":"A Berekmeri","year":"2018","unstructured":"Berekmeri A, Mahmood F, Wittmann M, Helliwell P (2018) Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 14(9):719\u2013730. https:\/\/doi.org\/10.1080\/1744666X.2018.1512404","journal-title":"Expert Rev Clin Immunol"},{"key":"6930_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","volume":"393","author":"N Crispino","year":"2021","unstructured":"Crispino N, Ciccia F (2021) JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 393:668\u201375","journal-title":"Clin Exp Rheumatol"},{"key":"6930_CR8","doi-asserted-by":"publisher","first-page":"662047","DOI":"10.3389\/fmolb.2021.662047","volume":"8","author":"AL Carvalho","year":"2021","unstructured":"Carvalho AL, Hedrich CM (2021) The molecular pathophysiology of psoriatic arthritis-the complex interplay between genetic predisposition, epigenetics factors, and the microbiome. Front Mol Biosci 8:662047. https:\/\/doi.org\/10.3389\/fmolb.2021.662047","journal-title":"Front Mol Biosci"},{"issue":"8","key":"6930_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","volume":"133","author":"M Chen","year":"2020","unstructured":"Chen M, Dai SM (2020) A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chin Med J (Engl) 133(8):959\u2013967. https:\/\/doi.org\/10.1097\/CM9.0000000000000711","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"6930_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","volume":"42","author":"ME Dowty","year":"2014","unstructured":"Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, Prakash C (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos 42(4):759\u2013773. https:\/\/doi.org\/10.1124\/dmd.113.054940","journal-title":"Drug Metab Dispos"},{"issue":"16","key":"6930_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377(16):1525\u20131536. https:\/\/doi.org\/10.1056\/NEJMoa1615977","journal-title":"N Engl J Med"},{"issue":"16","key":"6930_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieslak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"issue":"5","key":"6930_CR13","first-page":"874","volume":"38","author":"GO Littlejohn","year":"2020","unstructured":"Littlejohn GO, Tymms KE, Smith T, Griffiths HT (2020) Using big data from real-world Australian rheumatology encounters to enhance clinical care and research. Clin Exp Rheumatol 38(5):874\u2013880","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"6930_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3899\/jrheum.120594","volume":"40","author":"OR Madsen","year":"2013","unstructured":"Madsen OR (2013) Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biological agents in the daily clinic. J Rheumatol 40(4):379\u2013385. https:\/\/doi.org\/10.3899\/jrheum.120594","journal-title":"J Rheumatol"},{"issue":"2","key":"6930_CR15","doi-asserted-by":"publisher","first-page":"rkaa070","DOI":"10.1093\/rap\/rkaa070","volume":"4","author":"K Geale","year":"2020","unstructured":"Geale K, Lindberg I, Paulsson EC, Wennerstrom ECM, Tjarnlund A, Noel W, Enkusson D, Theander E (2020) Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract 4(2):rkaa070. https:\/\/doi.org\/10.1093\/rap\/rkaa070","journal-title":"Rheumatol Adv Pract"},{"issue":"5","key":"6930_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E (2022) Long-term Persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the french health insurance database. JAMA Dermatol 158(5):513\u2013522. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0364","journal-title":"JAMA Dermatol"},{"issue":"2","key":"6930_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3899\/jrheum.210159","volume":"49","author":"A Haddad","year":"2022","unstructured":"Haddad A, Saliba W, Lavi I, Batheesh A, Kasem S, Gazitt T, Feldhamer I, Cohen AD, Zisman D (2022) The Association of psoriatic arthritis with all-cause mortality and leading causes of death in psoriatic arthritis. J Rheumatol 49(2):165\u2013170. https:\/\/doi.org\/10.3899\/jrheum.210159","journal-title":"J Rheumatol"},{"issue":"9","key":"6930_CR18","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s10067-020-05021-7","volume":"39","author":"P Bird","year":"2020","unstructured":"Bird P, Littlejohn G, Butcher B, Smith T, da Fonseca PC, Witcombe D, Griffiths H (2020) Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clin Rheumatol 39(9):2545\u20132551. https:\/\/doi.org\/10.1007\/s10067-020-05021-7","journal-title":"Clin Rheumatol"},{"key":"6930_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/PPA.S167508","volume":"12","author":"MJ Murage","year":"2018","unstructured":"Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence 12:1483\u20131503. https:\/\/doi.org\/10.2147\/PPA.S167508","journal-title":"Patient Prefer Adherence"},{"key":"6930_CR20","doi-asserted-by":"publisher","first-page":"1759720X2210923","DOI":"10.1177\/1759720X221092376","volume":"14","author":"R Felten","year":"2022","unstructured":"Felten R, Lambert De Cursay G, Lespessailles E (2022) Is there still a place for methotrexate in severe psoriatic arthritis? Ther Adv Musculoskelet Dis 14:1759720X221092376. https:\/\/doi.org\/10.1177\/1759720X221092376","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"6930_CR21","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O\u2019Keeffe AG, Maddison PJ, Scott DL (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51(8):1368\u20131377. https:\/\/doi.org\/10.1093\/rheumatology\/kes001","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"6930_CR22","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB (2019) Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 71(7):1112\u20131124. https:\/\/doi.org\/10.1002\/art.40851","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"6930_CR23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewe RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6930_CR24","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1007\/s12325-022-02084-7","volume":"39","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A (2022) Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States healthcare claims database. Adv Ther 39(6):2932\u20132945. https:\/\/doi.org\/10.1007\/s12325-022-02084-7","journal-title":"Adv Ther"},{"issue":"1","key":"6930_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40744-021-00398-6","volume":"9","author":"WB Nowell","year":"2022","unstructured":"Nowell WB, Karis E, Gavigan K, Stradford L, Zhao H, Chen L, Stryker S, Yun H, Venkatachalam S, Kricorian G, Xie F, Curtis JR (2022) Patient-reported nausea and fatigue related to methotrexate: a prospective, self-controlled study in the arthritispower((R)) registry. Rheumatol Ther 9(1):207\u2013221. https:\/\/doi.org\/10.1007\/s40744-021-00398-6","journal-title":"Rheumatol Ther"},{"issue":"1","key":"6930_CR26","doi-asserted-by":"publisher","first-page":"e000596","DOI":"10.1136\/rmdopen-2017-000596","volume":"4","author":"KM Fagerli","year":"2018","unstructured":"Fagerli KM, Kearsley-Fleet L, Watson KD, Packham J, Contributors Group BR, Symmons DPM, Hyrich KL (2018) Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open 4(1):e000596. https:\/\/doi.org\/10.1136\/rmdopen-2017-000596","journal-title":"RMD Open"},{"issue":"2","key":"6930_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J, Group AS (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 74(2):354\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204128","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"6930_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3904\/kjim.2015.385","volume":"33","author":"EY Park","year":"2018","unstructured":"Park EY, Lee SG, Park EK, Koo DW, Park JH, Kim GT, Tag HS, Kim HO, Suh YS (2018) Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus. Korean J Intern Med 33(1):193\u2013202. https:\/\/doi.org\/10.3904\/kjim.2015.385","journal-title":"Korean J Intern Med"},{"key":"6930_CR29","doi-asserted-by":"publisher","first-page":"100601","DOI":"10.1016\/j.curtheres.2020.100601","volume":"93","author":"DD Gladman","year":"2020","unstructured":"Gladman DD, Orbai AM, Gomez-Reino J, Chang-Douglass S, Leoncini E, Burton HE, Kanik KS, Romero AB, Cappelleri JC, Hsu MA (2020) Network meta-analysis of tofacitinib, biologic disease-modifying antirheumatic drugs, and apremilast for the treatment of psoriatic arthritis. Curr Ther Res Clin Exp 93:100601. https:\/\/doi.org\/10.1016\/j.curtheres.2020.100601","journal-title":"Curr Ther Res Clin Exp"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06930-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06930-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06930-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T05:12:30Z","timestamp":1713157950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06930-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6930"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06930-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The activities of OPAL Rheumatology Ltd have received overarching ethics approval from the University of New South Wales (UNSW) Human Research Ethics Committee (HREC), based on a patient opt-out arrangement (HC17799).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This research protocol was approved by the UNSW HREC (HC200786). Opt-out arrangement for consent for research involving non-reidentifiable routine electronic medical records.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients have consented to the publication of data on an opt-out basis. All data are de-identified.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"COS and TS are employees of OPAL Rheumatology Ltd and declare no competing interests. JL and BB are independent statistical consultants, funded by OPAL. The following interests are declared for GL; Astra Zeneca, MF; AbbVie, Janssen, UCB, Pfizer and Lilly and PY; Abbvie, Eli Lilly, Celltrion, Pfizer, Sandoz. DW and HN are employees of Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}